Reevaluating aminosalicylates role in maintaining remission in ulcerative colitis: Systematic review and meta-analysis in the era of biologics
Abstract
BACKGROUND
Oral 5-aminosalicylic acid (5-ASA) has been a cornerstone treatment for mild to moderate ulcerative colitis (UC), traditionally used to maintain remission. With the rise of advanced therapies (biologics and small molecules), the role of 5-ASA has come under renewed scrutiny. While earlier systematic reviews affirmed its efficacy compared to placebo, these did not account for the advent of advanced therapies.
AIM
To assess the efficacy and safety of oral 5-ASA in maintaining remission in quiescent UC, compared to placebo, alternative 5-ASA formulations, and advanced therapies, in the era of biologics and small molecules.
METHODS
It was systematically searched MEDLINE, EMBASE, and the Cochrane Library, alongside conference proceedings (European Crohn’s and Colitis Organisation, British Society of Gastroenterology), for randomized controlled trials published between 2003 and 2024 in English. Eligible studies involved oral 5-ASA therapies for quiescent UC with a minimum treatment duration of six months. Outcomes included failure to maintain remission, adverse events, and serious adverse events (SAEs). Data were analyzed using Cochrane methods, with GRADE assessing evidence certainty.
RESULTS
From 44 studies (9967 participants), 5-ASA was superior to placebo in maintaining remission, with 37% of 5-ASA users relapsing at 6-12 months compared to 55% of placebo users [risk ratios (RR): 0.68; 95%CI: 0.61-0.76; high-certainty evidence]. SAEs were rare and comparable between…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 9,967 participants or records.
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.